I would say that everyone is quite well aware of the timeline....

I would say that everyone is quite well aware of the timeline. Many of the people that post here have held the stock since before the rise to $4.

You showcase to a very high standard how much you do not know about this company.

There are over 40 publications for Bisantrene in humans ranging from phase 1 to 3 (1), with two phase 2 trials being completed within the timeframe you are quoting a price target from (2,3). There are many reasons why the clinical trials that have been completed are important, but there are many more as to why improved clinical trials are needed. This has to do with the recent, world-first discoveries that have been made by external, independent research groups as well as within RAC (4,5). Both of these opportunities are considered blue ocean opportunities because there are no clinical or commercial competitors - considered the most essential building blocks for commercial success in biotechnology (6). Majority of takeovers happen in phase 2, which really is around the corner if a lot of us have been holding since 2020. Many shareholders, myself included, are prepared to wait the time required for the answers to our questions.

The reality is that the science is at a level where lines on a graph fail to grasp the enormity of the opportunity, and where people such as yourself without even a fingernails grasp on the clinical, biological, and physiological knowledge necessary to comprehend and appreciate this opportunity are likely to fall short in their assessments.

A lot of what you say sounds like fact, where it should sound more like questions.

1. https://www.opastpublishers.com/open-access-articles/the-rediscovery-of-bisantrene-a-review-of-the-literature.pdf
2. https://pubmed.ncbi.nlm.nih.gov/33159365/
3. https://ashpublications.org/blood/article/142/Supplement%201/4292/503407/Bisantrene-in-Combination-with-Fludarabine-and
4. https://pubmed.ncbi.nlm.nih.gov/32531268/
5. https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSDYL4Aa%2ByRj0v%2BV4%2FLFiGug%3D
6. https://web-assets.bcg.com/img-src/What_Matters_Most_Biopharma_tcm9-95831.pdf